Struggling Securing Funding? We can help.

By Imagine Biotech

Securing capital is hard. Securing capital for biotech ventures is even harder.

In a landscape where 90-95% of clinical drug developments fail, investors are wary— with good reason.

• $6MM - Average spend on pre-clinical toxicology studies 💵 

• 12 Years - Average time from bench to market for therapeutics 🕛️ 

• 45% Failure Rate due to limited pre-clinical efficacy 📉 

• 30% Failure Rate due to unmanageable toxicity 💀 

These statistics, coupled with already volatile market conditions, are the main contributing factors to investor hesitance. What if there was another way, perhaps a team of scientists, physicians, and business professionals with a common goal of helping biotech ventures secure funding?

🧪 Introducing Imagine Biotech 🖥️ 

With a team of experienced and accomplished scientific and business professionals, we understand the difficulties that come with a biotech venture. Securing capital, finding potential investors, and proving the merit behind your technology to investors are just some of the difficulties that come with trying to tackle the worlds toughest issues.

🤝 Tailored to Startups 🚀 

Providing access to capital and scientific backing for your discoveries is our specialty. Despite feeling like nobody wants to invest in biotech, the opposite is true— believe us, we have a growing portfolio of investors who see the potential in early stage drug development. We just have to point them in the right direction.

Not only can Imagine Biotech connect you with investors, we can do even better.

Scientific Due Diligence 🔍️ 📰 

Understanding new drug developments is hard for everyone, but even more so for investors with no scientific background. Our team can provide comprehensive Scientific Due Diligence reports that detail your development in a way that investors can understand.

What does Imagine Biotech Scientific Due Diligence look like? 🤔 

• Molecular Docking / Pre-clinical Toxicology Reports 🖥️ 📰 

  • With access to high powered systems, we can provide you with detailed structural analysis of your development along with predictions of toxicity— one of the leading causes for new drug failure.

• ADMET Prediction / PK Modeling 🖥️ 💊 

  • The ADMET and Pharmacokinetic profile of a drug is one of the most important, and telling signs, in regard to drug efficacy. Through quantum chemistry programs, our team is able to provide you with a comprehensive report of the ADMET and PK profile of your development.

• Strategic Advisory Consultancy 🧑‍💼🤝 

  • The scientific aspect of drug development is hard enough, it only becomes harder when business strategy is overlooked though. Considering regulatory and scientific factors, the professional reputation and operations of your company can be analyzed to help you appeal to investors and regulatory bodies alike.

• Risk Intelligence Reviews 🔍️🖋️ 

  • Creating financial models for early stage pharmaceutical developments is extremely difficult. Low success rates, long timelines, and expensive development protocols contribute to investor resistance. We can provide extensive projections to help investors accurately understand the current, and future value, of your venture.

• CMC Consulting 💭 ⚙️ 

  • Developing an IND application is a major milestone. With success in preclinical trials propelling you to this stage, the last thing you want is a holdup in pursuit of clinical trials. Crucial for ensuring quality, safety, and efficacy, our team can help with all aspects of drug development from initial design to wide scale manufacture.

When one of our reports hits the desk of a potential investor, you can be sure that there is a thorough, comprehensive, and unbiased representation of your company and therapeutic development. You’ve worked hard to push the boundaries of known treatments and our goal is to help you keep pushing for a better tomorrow.

We believe that informed investments are the cornerstone of progress. Our mission is to empower investors with the insights and tools necessary to navigate the complexities of biotech investments with confidence.